BioSpace News Archive

NeoGenomics, Inc. (NASDAQ:NEO) (the “Company”), a leading oncology testing services company, today announced its third-quarter results for the period ended September 30, 2023 as compared to September 30, 2022.

Neuronetics, Inc. announced the granting of inducement awards of Restricted Stock Units representing a total of 18,000 shares of the Company’s common stock to four new non-executive employees.

Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announced today it will host a conference call on November 13, 2023, at 4:30 PM Eastern Time to discuss results for its third quarter ended September 30, 2023.

Gilead Sciences, Inc. and Arcus Biosciences, Inc. announced that domvanalimab plus zimberelimab and chemotherapy showed encouraging overall response rate and six-month progression-free survival rate results in a preliminary analysis from Arm A1 of the EDGE-Gastric study.

Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced financial results for the three months ended September 30, 2023.

Daewoong Pharmaceutical (CEOs Seng-Ho Jeon and Chang-Jae Lee) announced on the 6th that it will commence full-scale development of an obesity treatment utilizing a microneedle patch loaded with GLP-1 (Glucagon-like peptide-1) analogues.

Novotech, the leading Asia Pacific centred biotech CRO with global execution capabilities, published the latest 2023 global clinical trial environment whitepaper focused on infectious diseases.

Aura Biosciences, Inc. announced the pricing of an underwritten public offering of 11,000,000 shares of its common stock at a price to the public of $9.00 per share.

OWKIN and 10x Genomics, Inc., announce they have entered into an agreement to add 10x Genomics spatial omics and single-cell technologies to the ambitious MOSAIC project, which has already garnered attention for its pioneering work in tumor analysis for therapeutic discovery.

Aadi Bioscience, Inc., a commercial-stage biopharmaceutical company focused on developing and commercializing precision therapies for genetically-defined cancers with alterations in mTOR pathway genes, announced participation in the Jefferies London Healthcare Conference, taking place November 14-16, 2023, in London.